Noble David W, Webster John
Department of Anaesthesia, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland.
Drug Saf. 2002;25(7):489-95. doi: 10.2165/00002018-200225070-00003.
Millions of patients undergo surgery each year and an increasing proportion of these patients are consuming therapeutic drugs. Drug therapy is often withheld in the immediate perioperative period and after major surgery, in particular, there is often a prolonged period of fasting. This may lead to withdrawal effects including recurrence or worsening of patients' disease symptomatology. These effects will occur during a period of physiological and pathophysiological stresses and render patients more vulnerable to drug withdrawal phenomena. Thus, patients may be exposed to greater and sometimes unnecessary risks in the perioperative period. There are relatively few studies that have investigated this problem. The ones that have, however, confirm that drug abstinence in the perioperative period is a relatively common phenomenon and one study has demonstrated an association between duration of drug abstinence and adverse outcomes. The pathophysiological effects of major surgery on gastrointestinal function, neuro-humoral and cytokine adaptive responses to surgical stress are under-appreciated. These responses can reduce the effectiveness of oral administration and exacerbate co-existing disease processes. These problems are compounded by a fragmented approach to perioperative drug therapy with no one group of healthcare professionals assuming responsibility for this aspect of care. This may in part be a consequence of the complexities of rationalising drug therapy in the perioperative period together with the lack of readily available and evidence based information strategies for individual drugs or drug classes. An additional problem relates to the formulations, inherent pharmacokinetics and limited routes of administration of many prescribed drugs. These can prevent a 'seamless' transition from preoperative to postoperative management. Consumers, health professionals, pharmaceutical companies and drug regulatory agencies must all play a part in rectifying this problem. There remains a need for further research to clarify the effects of abstinence on patient outcomes and also to identify optimum strategies to avoid unwanted drug abstinence.
每年有数百万患者接受手术,且这些患者中使用治疗性药物的比例日益增加。在围手术期即刻以及大手术后,药物治疗常常被中断,尤其是通常会有一段较长时间的禁食期。这可能导致戒断效应,包括患者疾病症状的复发或加重。这些效应会在生理和病理生理应激期间出现,使患者更容易出现药物戒断现象。因此,患者在围手术期可能面临更大且有时是不必要的风险。针对这一问题进行调查的研究相对较少。然而,已有的研究证实围手术期药物戒断是一种较为常见的现象,并且有一项研究表明药物戒断持续时间与不良后果之间存在关联。大手术对胃肠功能、神经体液以及细胞因子对外科手术应激的适应性反应所产生的病理生理效应尚未得到充分认识。这些反应会降低口服给药的效果,并加剧并存的疾病进程。围手术期药物治疗方法零散,没有一组医疗保健专业人员负责这方面的护理,这些问题因而更加复杂。这可能部分是由于围手术期药物治疗合理化的复杂性,以及缺乏针对个别药物或药物类别随时可用且基于证据的信息策略。另一个问题涉及许多处方药的剂型、固有的药代动力学以及有限的给药途径。这些因素会妨碍从术前到术后管理的“无缝”过渡。消费者、卫生专业人员、制药公司和药品监管机构都必须在解决这一问题中发挥作用。仍需要进一步研究以阐明戒断对患者预后的影响,并确定避免不必要药物戒断的最佳策略。